PMID

Data

Article Title

Organization

Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.

Merck Research Laboratories

Synthesis and biological activity of N-substituted aminocarbonyl-1,3-dioxolanes as VLA-4 antagonists.

New Drug Discovery Research

Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists.

Merck Research Laboratories

Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.

Merck Research Laboratories

A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid.

Daiichi Sankyo

Selectively targeting T- and B-cell lymphomas: a benzothiazole antagonist of alpha4beta1 integrin.

University of California Davis

Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist.

Daiichi Sankyo

Imidazopyridines as VLA-4 integrin antagonists.

Ucb Pharma

Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives.

Kyowa Hakko Kogyo

The design and synthesis of potent cyclic peptide VCAM-VLA-4 antagonists incorporating an achiral Asp-Pro mimetic.

Roche Research Center

Cyclic thioether peptide mimetics as VCAM-VLA-4 antagonists.

Roche Research Center

Carbacyclic peptide mimetics as VCAM-VLA-4 antagonists.

Roche Research Center

Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

Massachusetts General Hospital and Harvard Medical School